Novo Nordisk Pledges $200 Million to Diabetes Fight as Pipeline Notches EU Win and New Filings

Novo Nordisk has committed USD 200 million to the World Diabetes Foundation, a pledge running from 2027 through 2036 that will fund diabetes prevention and care in low- and middle-income countries. The company announced the commitment on Wednesday, framing it around both heading off the disease and supporting people already living with it.

The philanthropic move capped a busy stretch for the Danish drugmaker, whose shares rose 2.7% on Friday — a gain the company has not tied to any single disclosure.

Real-World Data, With a Caveat

At ObesityWeek, Novo Nordisk presented findings from the SIGNAL and OCTANE analyses on Wegovy. According to the company, the measures of mental preoccupation with food fell in both evaluations. Because these are observational studies, however, they cannot establish a causal link.

The same week brought a regulatory footnote for the GLP-1 franchise. On 9 November, the US Food and Drug Administration ordered manufacturers of GLP-1 medicines to add a warning about possible rare vision loss linked to NAION. The FDA put the incidence at roughly six cases per 100,000 patients who had taken a GLP-1 drug for at least a year, according to the Associated Press. Novo Nordisk, as reported by the Washington Post, continues to view the benefit-risk profile of semaglutide as favourable.

Guidance Lifted After a Strong Quarter

Financial momentum was already on display on 4 November, when Novo Nordisk raised its full-year outlook. For 2026, the company now projects currency-adjusted growth in both adjusted sales and adjusted operating profit of between -2% and +2%.

Adjusted operating profit for the third quarter of 2026 climbed 27% at constant exchange rates, reaching DKK 31.7 billion, per the company's mandatory disclosure.

A European Green Light — and Two New Filings

Friday also delivered an approval from the European Commission for FREHEMGO (denecimig), cleared for routine prevention or reduction of bleeding in adults and children with haemophilia A, with or without inhibitors. Dosing can be weekly, every two weeks or monthly, and Novo Nordisk expects the first European launches next year.

On the same day, the company filed for approval of Etavopivat with both the FDA and the EMA. The once-daily investigational treatment for sickle cell disease targets adolescents and adults, rests on results from the Phase 3 HIBISCUS trial, and could see regulatory decisions in 2027.

CagriSema Data in The Lancet

Novo Nordisk also released results from the Phase 3 REDEFINE 9 study of its investigational CagriSema, presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology.